title: Meta-analysis technique confirms the effectiveness of anti-TNF-alpha in the management of active ulcerative colitis when administered in combination with corticosteroids.
abstract: BACKGROUND
  TNF-alpha has an important role in the pathogenesis of ulcerative colitis (UC). It therefore seems that infliximab, the antibody against TNF-alpha, is beneficial in the treatment of UC. The aim was to determine whether infliximab induces clinical response and remission in patients with UC using the meta-analysis technique.
  
  
  METHODS
  The Pubmed and Embase databases were searched for studies investigating the efficacy of infliximab on UC. Data from 1966 to 2006 were collected. The keywords used to search were "ulcerative colitis" with "infliximab", "anti tumor necrosis factor", or "anti tumor necrosis factors". The reference lists from the retrieved articles were also reviewed for additional applicable studies.
  
  
  RESULTS
  The summary odds ratio (OR) for clinical remission in four studies was 3.24 with a 95%CI of 1.6-6.57 and a significant OR. The summary OR for clinical response in three studies was 3.93 with a 95%CI of 2.84-5.45 and a significant OR.
  
  
  CONCLUSIONS
  Infliximab is effective in inducing response and remission in patients with ulcerative colitis when administered in combination with corticosteroids.
authors.affiliation: Faculty of Pharmacy, and Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences, Tehran, Iran.
authors.forename: Roja
authors.initials: R
authors.lastname: Rahimi
authors.forename: Shekoufeh
authors.initials: S
authors.lastname: Nikfar
authors.forename: Mohammad
authors.initials: M
authors.lastname: Abdollahi
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use*; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D003093:Colitis, Ulcerative / Q000628:therapy*; D005260:Female; D006801:Humans; D000069285:Infliximab; D008297:Male; D008954:Models, Biological; D016017:Odds Ratio; D010919:Placebos; D016032:Randomized Controlled Trials as Topic; D012074:Remission Induction; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000737:chemistry*
chemical_list: D000305:Adrenal Cortex Hormones; D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D010919:Placebos; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab